RADX to meet U.S. FDA on RAD 101 Phase 3 trial design
Radiopharm Theranostics (RADX) says it will meet with the U.S. FDA to align on pivotal Phase 3 trial design for RAD 101 in the diagnosis of brain metastases.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.